In the final months of 2025, MacroGenics Inc. (MGNX) finds itself at a crossroads. Years of scientific ambition, clinical trial execution, and partnership negotiations are converging into a moment that could reshape the company's future. The lab-born promise of lorigerlimab, the quiet momentum behind its ADC pipeline, and the weight of milestone-rich agreements with industry giants like Gilead, Incyte, and Sanofi are no longer abstract possibilities; they are now time-sensitive decisions.
The company's path forward is being charted not just by data, but by timing. Two Phase 2 trials for lorigerlimab are nearing critical updates. Early-stage ADCs are inching toward proof-of-concept. Preclinical candidates are being readied for FDA submission. Meanwhile, the company's cash position, once bolstered by asset sales and royalty deals, is being stretched across a runway that must last through mid-2027.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.